Treosulfan and gemcitabine in metastatic uveal melanoma patients: Results of a multicenter feasibility study

Anti-Cancer Drugs

Volumn 14, Issue 5, 2003, Pages 337-340

  Pföhler, Claudia ^a   Cree, Ian A ^b   Ugurel, Selma ^a   Kuwert, Christoph ^c   Haass, Nikolas ^c   Neuber, Karsten ^c   Hengge, Ulrich ^d   Corrie, Pippa G ^e   Zutt, Markus ^f   Tilgen, Wolfgang ^a   Reinhold, Uwe ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Chemotherapy; Choroidal melanoma; Gemcitabine; Treosulfan

Indexed keywords

GEMCITABINE; TREOSULFAN;

ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; EUROPE; FEMALE; HAIR LOSS; HUMAN; MALE; MEDICAL ASSESSMENT; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL RATE; UVEA MELANOMA;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; MELANOMA; MIDDLE AGED; PILOT PROJECTS; SURVIVAL ANALYSIS; UVEAL NEOPLASMS;

EID: 0037841353     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200306000-00002     Document Type: Article

References (20)

1. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res 2001; 11:255-263.
2. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffgen K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993; 72:2219-2232.
3. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the MD Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
4. McNamara M, Clynes M, Dunne B. Multidrug resistance in ocular melanoma. Br J Ophthalmol 1996; 80:1009-1012.
5. Jäckel A, Dock M, Deichmann M, Waldmann V, Näher H. Therapy of metastatic malignant uveal melanoma. Hautarzt 2001; 52:98-103.
6. Becker JC, Kämpgen E, Bröcker EB. Classical chemotherapy for metastatic melanoma. Clin Exp Dermatol 2000; 25:503-508.
7. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 1998; 24:127-130.
8. Leyvraz S, Spataro V, Bauer J, Pampellona S, Salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589-2595.
9. Nathan FE, Berd D, Sato T, Shield JA, Shields CL, De Potter P, et al. BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res 1997; 16:201-208.
10. Myatt N, Cree IA, Kurbacher CM, Fross AJE, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroideal melanoma. Anticancer Drugs 1997; 8:756-762.
11. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, et al. Combination chemotherapy for choroideal melanoma: ex vivo chemosensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79:1487-1493.
12. Neale MH, Myatt NE, Khoury GG, Weaver P, Lamont A, Hungerford JL, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001; 11:601-609.
13. Neuber K, tom Dieck A, Blödorn-Schlicht N, Itschert G, Karnbach C. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res 1999; 9:125-132.
14. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication 48. Geneva: WHO; 1979.
15. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999; 9:575-581.
16. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996; 41:215-228.
17. Cantore M, Fiorentini G, Aitini E, Davitti B, Cavazzini G, Rabbi C, et al. Intraarterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori 1994; 80:37-39.
18. Cutler SJ, Scotta J, Devesa SS, Connelly RR. Third National Cancer Survey: an overview of available information. J Natl Cancer Inst 1974; 53:1565-1575.
19. Kurbacher CM, Grecu OM, Stier U, Gilster TJ, Janat MM, Untch M, et al. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials. Rec Res Cancer Res 2003; 161:221-230.
20. Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6:488-495.